RegInfo: The international database of regulated information of listed companies

SEARCH BY

Issuer directory

KEYWORDS

COMPANIES / ISIN

TYPE OF INFORMATION

INDUSTRY

ADVANCED SEARCH

COMPARTMENTS / INDICES

France

America

Asia

Oceania

> ASX 20
Australia - ASX 20
> NZX 15
New Zealand - NZX 15

Africa

> FTSE/JSE...
South Africa - FTSE/JSE Top 40
> TA 25
Israel - TA 25
- ALONY HETZ
- AZRIELI GROUP
- BAZAN
- BEZEQ
- DELEK DRILLIN
- DELEK GROUP
- DISCOUNT
- ELBIT SYSTEMS
- Energean Oil Gas
- FIBI BANK
- GAZIT GLOBE
- HAREL
- ICL
- IFF
- ISRAEL CORP
- LEUMI
- LivePerson
- MIZRAHI TEFAHOT
- NICE
- OPKO HEALTH
- ORMAT
- PAZ OIL
- PERRIGO
- Phoenix Group Holdings
- POALIM
- SHUFERSAL
- STRAUSS GROUP
- TEVA
- TOWER JAZZ

Europe

TYPE OF INFORMATION SEARCH RESULT

2021.05.13 | 08:00 | Public offerings / Squeeze Out

Nordecon

puce Construction contract (Concrete works of Kemi bioproduct mill) - HTML (w)

2021.05.12 | 16:51 | / Prospectus

Royal Dutch Shell plc

puce Publication of Prospectus Supplement - HTML (w)

2021.05.12 | 16:51 | / Prospectus

Royal Dutch Shell plc

puce Publication of Prospectus Supplement - HTML (w)

2021.05.12 | 16:51 | / Prospectus

Royal Dutch Shell plc

puce Publication of Prospectus Supplement - HTML (w)

2021.05.04 | 07:30 | Public offerings / Squeeze Out

NICOX

puce Nicox’s Licensee Bausch + Lomb Launches VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024% in Taiwan and Receives Approval in Qatar - HTML (w)

2021.05.04 | 07:30 | Public offerings / Squeeze Out

NICOX

puce Nicox : Lancement de VYZULTA® (solution ophtalmique de latanoprostène bunod), 0,024% à Taiwan par son partenaire Bausch + Lomb - Approbation de VYZULTA® au Qatar - HTML (w)

2021.05.03 | 19:25 | Public offerings / Squeeze Out

Videlio

puce Projet d'offre publique d’achat simplifiée suivie d'un retrait obligatoire visant les actions VIDELIO - HTML (w)

2021.04.27 | 07:30 | Public offerings / Squeeze Out

NICOX

puce U.S. Patent Office Issues Notice of Allowance for Nicox’s Latanoprostene Bunod in Normal Tension Glaucoma - HTML (w)

2021.04.27 | 07:30 | Public offerings / Squeeze Out

NICOX

puce Nicox : Avis de délivrance du brevet pour le latanoprostène bunod dans le glaucome à tension normale par l’Office Américain des Brevets - HTML (w)

2021.04.23 | 17:45 | Public offerings / Squeeze Out

Vinci

puce VINCI Concessions and Eiffage enter into an agreement for exclusive negotiations with a view to file a simplified tender offer, followed by a squeeze-out, if the conditions for implementation are met, for the shares of Société Marseillaise - HTML (w)

2021.04.23 | 17:45 | Public offerings / Squeeze Out

Vinci

puce Conclusion d’un accord de négociations exclusives entre VINCI Concessions et Eiffage en vue d’une offre publique d’achat simplifiée, suivie le cas échéant d’un retrait obligatoire, visant les actions de la Société Marseillaise du Tunnel Pra - HTML (w)

2021.04.22 | 07:30 | Public offerings / Squeeze Out

NICOX

puce U.S. Patents for Nicox’s Latanoprostene Bunod, Commercialized as VYZULTA®, Eligible for Patent Term Extension - HTML (w)

2021.04.22 | 07:30 | Public offerings / Squeeze Out

NICOX

puce Nicox : Eligibilité à une extension de la durée de brevets américains couvrant le latanoprostène bunod commercialisé sous le nom de VYZULTA® - HTML (w)

2021.04.16 | 07:30 | Public offerings / Squeeze Out

NICOX

puce BAUSCH HEALTH ANNOUNCES VYZULTA® (LATANOPROSTENE BUNOD OPHTHALMIC SOLUTION), 0.024%, IS NOW APPROVED IN BRAZIL - HTML (w)

2021.04.16 | 07:30 | Public offerings / Squeeze Out

NICOX

puce BAUSCH HEALTH ANNONCE L’APPROBATION DE VYZULTA® (SOLUTION OPHTALMIQUE DE LATANOPROSTENE BUNOD), 0,024% AU BRESIL - HTML (w)

Pages : 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 / Doc nb : 1000